Đang chuẩn bị liên kết để tải về tài liệu:
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled openlabel phase II trial

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). | Stereotactic ablative body radiotherapy SABR combined with immunotherapy L19-IL2 versus standard of care in stage IV NSCLC patients ImmunoSABR A multicentre randomised controlled openlabel phase II trial

TÀI LIỆU LIÊN QUAN

Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): A randomized controlled trial

Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors

Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)

Oligometastases from prostate cancer: Local treatment with stereotactic body radiotherapy (SBRT)

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage nonsmall cell lung cancer

Single fraction ablative preoperative radiation treatment for early-stage breast cancer: The CRYSTAL study – a phase I/II clinical trial protocol

Management of patients with early stage lung cancer – why do some patients not receive treatment with curative intent?